Quadrant Capital Group’s Neurogene NGNE Stock Holding History

Quadrant Capital Group’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-25	Closed	-$2K	–	2626
2021 Q4	$2K	Buy	+25	New	+$3.05K	﹤0.01%	2159

Other funds holding NGNE

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Quadrant Capital Group's NGNE Position: Q1 2022 in Review

Quadrant Capital Group sold out of Neurogene (NGNE) in Q1 2022, closing a stake of 25 shares — an estimated $2K sold.

Quadrant Capital Group first reported a position in NGNE in Q4 2021 and held it in 1 quarter. The position peaked at $2K in Q4 2021. 81 funds tracked by Wall St. Rank hold NGNE as of Q1 2022.

Quadrant Capital Group reported no remaining Neurogene position as of Q1 2022 after selling out during the quarter.
Quadrant Capital Group sold 25 Neurogene shares in Q1 2022, an estimated $2K.
Quadrant Capital Group first reported a position in Neurogene in Q4 2021 and held it in 1 quarter.
Quadrant Capital Group's Neurogene position peaked at $2K in Q4 2021.
81 funds tracked by Wall St. Rank held Neurogene as of Q1 2022.

Based on Quadrant Capital Group's 13F filing for Q1 2022, filed 6 May 2022.